Immix Biopharma, Inc. (NASDAQ:IMMX – Get Free Report) was the target of a significant growth in short interest in the month of September. As of September 30th, there was short interest totalling 552,800 shares, a growth of 15.2% from the September 15th total of 479,700 shares. Based on an average daily trading volume, of 144,200 shares, the short-interest ratio is presently 3.8 days. Approximately 3.4% of the company’s shares are short sold.
Wall Street Analyst Weigh In
Separately, HC Wainwright reiterated a “buy” rating and issued a $7.00 target price on shares of Immix Biopharma in a report on Thursday, October 3rd.
View Our Latest Research Report on IMMX
Immix Biopharma Stock Down 4.0 %
Immix Biopharma (NASDAQ:IMMX – Get Free Report) last announced its quarterly earnings data on Monday, August 12th. The company reported ($0.15) EPS for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.06. As a group, analysts forecast that Immix Biopharma will post -0.64 earnings per share for the current year.
Hedge Funds Weigh In On Immix Biopharma
An institutional investor recently bought a new position in Immix Biopharma stock. Invst LLC bought a new position in shares of Immix Biopharma, Inc. (NASDAQ:IMMX – Free Report) during the second quarter, according to its most recent Form 13F filing with the SEC. The fund bought 27,000 shares of the company’s stock, valued at approximately $57,000. Invst LLC owned about 0.10% of Immix Biopharma at the end of the most recent reporting period. Hedge funds and other institutional investors own 11.26% of the company’s stock.
Immix Biopharma Company Profile
Immix Biopharma, Inc, a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease.
Read More
- Five stocks we like better than Immix Biopharma
- Technology Stocks Explained: Here’s What to Know About Tech
- Taiwan Semiconductor Stock: Buy Now or Wait for Earnings?
- Where Do I Find 52-Week Highs and Lows?
- Abbott’s Growth and Dividends Make It a Smart Portfolio Pick
- What is the Hang Seng index?
- Citigroup Faces Growing Troubles: Could the Industry Be at Risk?
Receive News & Ratings for Immix Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immix Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.